This site is intended for US healthcare professionals. If you are not a healthcare professional, click here
Fighting for a new era of cancer care
With over 2 decades of scientific innovation across oncology, Pfizer continues to drive the next wave of cancer breakthroughs. Approximately 40% of all our research and development investment is directed toward oncology.
We're dedicated to developing therapies in 4 key cancer types, including breast, genitourinary, hematologic, and thoracic cancers. This work spans 3 core modalities to attack cancer from multiple angles: small molecules, antibody-drug conjugates (ADCs), and immuno-oncology biologics, including bispecific antibodies.
Looking into the future with 50+ programs in development
We are working to develop new potential standards of care in some of the world's most common cancers, including breast, genitourinary, hematologic, and thoracic cancers.
Learn about our 80+ oncology clinical trials worldwide
Our clinical trials span nearly 4,000 study sites around the globe.
Attacking cancer from multiple angles
Our research spans 3 main modalities where we have significant depth, world-class capabilities, and expertise.
Antibody-drug conjugates
Antibody-drug conjugates bind to cancer cell proteins to deliver cytotoxic drugs directly to tumors.
Bispecifics
Bispecifics grab both the intended target cancer cell and an immune cell, bringing them close enough together for the immune cell to destroy the cancer cell.
Small molecules
Small molecules get inside cancer cells and disrupt their growth and progression. With a legacy of transforming treatment for certain cancers, we are researching novel small molecule medicines that have the potential to overcome treatment resistance and other challenges.
Supporting your patients with key resources
Regulating Rx costs
Understand how the Inflation Reduction Act (IRA) is lowering certain prescription costs.
Change the OddsTM
Learn how Pfizer is supporting American Cancer Society (ACS) to bridge gaps in cancer care disparities.